Blocking the PD-1/PD-L1 pathway can normalize anti-tumor responses, but PD-1 inhibitors are not recommended to treat unselected DLBCL patients, due to low expression of PD-1/PD-L1 in DLBCL. Here, CD274 is linked to diffuse large B-cell lymphoma.